Resumo

BENALCAZAR FREIRE, Juan Francisco; TIPANTAXI FLORES, Sabina Salomé  e  BENITEZ GUERRERO, Mishell Alexandra. SARS-CoV-2 and venous thromboembolic disease. Not everything is new. Angiología [online]. 2020, vol.72, n.6, pp.286-297.  Epub 01-Fev-2021. ISSN 1695-2987.  https://dx.doi.org/10.20960/angiologia.00173.

SARS-CoV-2, responsible for the pandemic; has shown a high thrombogenic potential, but; despite being a newly emerging virus, it shows a close relationship with previously described pathophysiological mechanisms.

Venous thromboembolic disease is the most frequent complication and it is directly proportional to the increase in mortality in these patients. In SARS-CoV-2 context, heparins have shown superiority over other drugs for their anti-inflammatory effect but there is not an established consensus about their dosage in different stages of the disease; moreover, at hospital discharge, the most suitable drug choice and pharmacological prophylaxis duration is controversial.

After an exhaustive review and based in both, current COVID-19 era literature and the past years related scientific information, we propose sepsis-induced coagulopathy (SIC) score and D-dimer quantification as objective parameters; in addition, we suggest the use of previously validated scores to assess venous thromboembolic risk, bleeding and diagnostic suspicion of deep vein thrombosis and pulmonary embolism; these could help to reduce subjective bias and try to clear uncertainties about this topic.

Palavras-chave : COVID-19; SARS-CoV-2; Coronavirus; Thrombosis; Venous thrombosis; Pulmonary embolism; Anticoagulants.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )